Results 231 to 240 of about 640,319 (303)

Type 2 diabetes mellitus as a state of altered drug pharmacokinetic-pharmacodynamic parameters: an update on recent developments and clinical implications. [PDF]

Ther Adv Endocrinol Metab
Sibiya N, Onyekwuluje C, Kuretu A, Ayodele O, Ngcobo N, Ngubane P, Khathi A.   +6 more
europepmc   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions. [PDF]

Pharmacol Res Perspect
Hosseini SA, Valadbeigi H, Khoshnazar SM, Khoshnood S, Falahi S, Rezaee D, Hematian A, Haddadi MH.   +7 more
europepmc   +1 more source

Levodopa: A novel therapeutic prospect for liver disease. [PDF]

World J Hepatol
Xu J, Qian Y, Wang JM, Wu XL, Zheng YY.
europepmc   +1 more source

Analysis of risk factors for herb-induced liver injury: a retrospective study from China. [PDF]

Front Pharmacol
Wang P, Liang X, Cheng G, Fan Q, Li Q, Dai F, Liu Y, Jiang Z, Luo T, Hu J, Dun W.   +10 more
europepmc   +1 more source

Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy. [PDF]

Clin Exp Med
Abdel-Rasol MA, El-Sayed WM.
europepmc   +1 more source

Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential. [PDF]

Drug Des Devel Ther
Wen W, Xia J, Liu G, Wang C.
europepmc   +1 more source